CD274 and non-small cell lung carcinoma: Of note, the pivotal phase 3 LUNAR study identified a clinically significant improvement in OS in patients with metastatic NSCLC who received TTFields therapy concomitant with a PD-(L)1 inhibitor compared with those receiving PD-(L)1 inhibitor alone (18.5 months vs 10.8 months, HR 0.63 [0.41–0.96]; p = 0.03) [36].